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ABSTRACT 
Objective: Major depressive disorder (MDD) is associated with an estimated fourfold 
risk for premature death, largely attributed to cardiovascular disorders. Pericardial 
adipose tissue (PAT), a fat compartment surrounding the heart, has been implicated 
in the development of coronary artery disease. An unanswered question is whether 
people with chronic MDD are more likely to have elevated PAT volumes versus acute 
MDD and controls (CTRL).  
 
Methods: The study group consists of sixteen patients with chronic MDD, thirty-four 
patients with acute MDD, and twenty-five CTRL. PAT and adrenal gland volume were 
measured by magnetic resonance tomography. Additional measures comprised 
factors of the metabolic syndrome, cortisol, relative insulin resistance, and pro-
inflammatory cytokines (interleukin-6; IL-6 and tumor necrosis factor-α, TNF-α).  
 
Results: PAT volumes were significantly increased in patients with chronic MDD > 
patients with acute MDD > CTRL. Adrenal gland volume was slightly enlarged in 
patients with chronic MDD > acute MDD > CTRL, although this difference failed to 
reach significance. The PAT volume was correlated with adrenal gland volume, and 
cortisol concentrations were correlated with depression severity, measured by BDI-2 
and MADRS. Group differences were found concerning the rate of the metabolic 
syndrome, being most frequent in chronic MDD > acute MDD > CTRL. Further 
findings comprised increased fasting cortisol, increased TNF-α concentration, and 
decreased physical activity level in MDD compared to CTRL.  
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Conclusion: Our results extend the existing literature in demonstrating that patients 
with chronic MDD have the highest risk for developing cardiovascular disorders, 
indicated by the highest PAT volume prevalence of metabolic syndrome. The 
correlation of PAT with adrenal gland volume underscores the role of the 
hypothalamus-pituitary-adrenal system as mediator for body-composition changes. 
Metabolic monitoring, health advices and motivation for the improvement of physical 
fitness may be recommended in depressed patients, in particular in chronic 
depression.  
 
Key words: chronic major depressive disorder, cardio-vascular disorder, pericardial 
adipose tissue, body composition, hypothalamus-pituitary-adrenal system 
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Introduction 
Chronic major depressive disorder (MDD) is defined as a major depressive episode 
without remission for at least two years. Chronic MDD is common, with a lifetime 
prevalence of ~5% in the general population; around 20-30% of acutely depressed 
individuals typically go on to develop a chronic disease course (1, 2). Chronic MDD is 
distinguished from acute MDD by an earlier onset (1), increased comorbidity with axis 
1 disorders (1, 3, 4), higher rates of personality disorders (5), higher rates of 
childhood trauma (6), greater suicidality (7) and functional impairment (1, 8), higher 
rates of mood disorders in relatives (9, 10), and worse treatment outcome (11-13). 
Chronic MDD is associated with significant individual and societal costs, documented 
by higher unemployment rates and lower rates of marriages across this patient group 
(14). 
 
The comorbidity of acute MDD with coronary artery disease (CAD) is common, and 
has also been observed in patients with chronic MDD (14). Depression and coronary 
artery disease are considered to have a bidirectional relationship. Recent studies 
examining depression as a risk factor for developing CAD have found increased rates 
of incident cardiovascular disease (15) and ischemic heart disease mortality (16). 
The underlying mechanisms that link MDD with cardio-metabolic disorders are 
complex.  Key factors contributing include the increased rate of the metabolic 
syndrome in MDD (17), increased rates of type-2 diabetes mellitus (18, 19), 
increased intra-abdominal adipose tissue (20), dysregulation of the hypothalamus-
pituitary-adrenal axis (HPAS) with subsequent alterations in cortisol concentrations 
(21), dysregulation of pro- and anti-inflammatory cytokines (22), and poor lifestyle 
habits (e.g. smoking, physical activity, dietary factors) (2, 23, 24).  
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Recently, increased pericardial adipose tissue (PAT) has been observed in patients 
with acute MDD (25). PAT is a fat deposit surrounding the heart, with close anatomic 
proximity to coronary arteries. Research from the general population has shown that 
similarly to intra-abdominal adipose tissue, PAT secretes pro-inflammatory cytokines 
that may be implicated in early-stage CAD (26). PAT is strongly associated with 
myocardial ischemia and coronary heart disease, even after adjusting for body mass 
index (27) and other cardiovascular risk factors (28, 29).  The results of general 
population-based studies have demonstrated that PAT is positively correlated with 
coronary artery calcification (30), inflammatory markers, and carotid intima-media 
thickness (31, 32). 
 
To the best of our knowledge, to date, no study has investigated if PAT volume 
differs among people with chronic MDD compared to those with acute MDD or 
controls. Therefore, our primary aim was to examine PAT volumes in patients with 
chronic MDD by cardiac magnetic resonance imaging (33), and to relate PAT 
volumes to adrenal gland volumes, a proxy parameter for HPAS activation.  Our main 
hypothesis was that chronic MDD is associated with higher PAT volumes and worse 
metabolic parameters compared to patients with acute MDD and healthy controls.  
 
Methods 
Study procedure and eligibility criteria 
The recruitment process, including the eligibility criteria are described in details 
elsewhere (25). In short, all patients were recruited after written informed consent at 
the Department of Psychiatry, Social Psychiatry and Psychotherapy of Hannover 
Medical School, and diagnosed according to the Diagnostic and Statistical Manual of 
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Mental Disorders, Fourth Edition (DSM-IV-TR) criteria, confirmed by standardized 
clinical interviews (SCID I/II; German version). 
Exclusion criteria included comprised acute or chronic infectious disease, lifetime 
immune or autoimmune disorders, type-2 diabetes mellitus, lifetime or current 
cardiovascular disease, pregnancy, schizophrenia, mental retardation, bipolar 
disorder, current substance abuse age younger than 18 and older than 60 years (25).   
 
PARTICIPANTS 
The current study utilizes data from an ongoing study including two groups of people 
with depression.  First, adults with acute MDD (N=34) were defined as those with a 
major depressive episode, defined as major depression with a duration less than two 
years, and no comorbidity with dysthymic disorder (N = 34).  Second, the chronic 
MDD group (N=16) was defined as those with MDD with comorbid dysthymic 
disorder, or MDD with a duration longer than two years, or MDD with partial response 
but still fulfilling MDD criteria (25). All patients were treated with psychotherapy, 
and 40/50 patients received psychopharmacological drugs. In particular, 16 
patients were treated with selective serotonine reuptake inhibitors, 11 with 
agomelatine, nine with dopamine and noradrenaline reuptake inhibitors, eight 
with selective serotonine and  noradrenaline reuptake inhibitors, three with 
quetiapine, and one patient received lithium. Eight of sixteen patients in the 
chronic MDD group reported an onset of the disorder before the age of 20y, 
compared to seven of thirty-four patients in the acute depression group. 
Twenty-five healthy subjects (CTRL) were recruited through announcements on 
university bulletin boards. Potential control subjects with mental and physical 
disorders were excluded, determined by using a standardized psychiatric interview 
and a physical examination.  
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BEHAVIORAL ASSESSMENTS 
Depression severity was assessed using the German versions of the 10-item, 
clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS) and the self-
reported, 21-item Beck Depression Inventory (34). Physical activity was assessed 
using a 6-point Likert scale with descriptors ranging from “never” (1) to “very often”  
(35). Smoking habits were measured in pack-years (the number of cigarettes smoked 
per day x years of smoking/20), and alcohol consumption was measured in drinks 
consumed per week.  
 
MAGNETIC RESONANCE IMAGING  
Pericardial adipose tissue (PAT) and adrenal gland volume were examined using a 
1.5 Tesla MRI scanner (Avanto, Siemens Healthcare) (36). To quantify PAT, ECG-
gated T1-weighted dark-blood turbo spin-echo sequences were acquired in short- 
and long-axis views at the following specifications: TR/TE = 750/37 ms, flip angle = 
180°, matrix = 384x187, field of view = 380 mm, and slice thickness = 10 mm. PAT 
was quantified between the atrioventricular plane and the apex by segmentation 
using QMass 7.1 software (Medis, Leiden, The Netherlands).  
Adrenal gland volumes were determined using a VIBE Dixon sequence with 2 mm 
slice thickness and QMass 7.1 software (Medis, Leiden, The Netherlands) by manual 
segmentation. To obtain the intra-observer variability the manual segmentation of the 
adrenal glands was done twice. Volumes of right and left adrenal gland were added, 
and expressed as total adrenal gland volume.  
All measurements were performed by raters blinded for the status of study 
participants.  
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BLOOD SAMPLING 
Fasting serum samples were collected between 0700 h and 0800 h and stored at -
80°C until the analysis. Concentrations of fasting glucose and fasting cortisol were 
determined with established immunoassays (Roche Diagnostics, Mannheim, Baden-
Württemberg, Germany). Concentrations of tumor necrosis factor-α (TNF-α) and 
interleukin-6 (IL-6) were determined using high sensitivity ELISA kits according to the 
manufacturer’s instructions (HS Quantikinine; R&D Systems, Wiesbaden, Germany). 
Relative insulin resistance was determined using the homeostasis assessment model  
(37). 
 
STATISTICAL ANALYSIS 
Data were analyzed using IBM SPSS Statistics (version 23). Group differences 
concerning PAT were determined utilizing ANCOVA. Since it was previously 
demonstrated that gender and age make an essential contribution to the amount of 
cardiac adipose tissue, we used group and gender as independent variables, PAT as 
dependent variable, and age, height and weight as potential confounders for the 
analysis of group differences concerning PAT (25) (38). Group differences 
concerning adrenal gland volume were analyzed using ANCOVA, with group as 
independent variable, adrenal gland volume as dependent variable, and age, height 
and weight as potential confounders. Anthropometric measures, factors of the 
metabolic syndrome, immune and endocrine measures were analyzed using ANOVA. 
The chi-squared test was used to compare the incidence of metabolic syndrome 
between groups, as defined according to ATP III criteria (39), and to compare 
categorical variables were appropriate. Partial correlations controlling for age, height 
and weight were calculated when testing for correlations between PAT, adrenal gland 
volume, endocrine (cortisol) measures, immune (TNF-α) measures and physical 
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activity. Values are presented as mean  SD. All P values <0.05 were considered to 
be significant.  
 
Results 
Full details of the demographics and clinical variables for the control, acute and 
chronic MDD groups are summarized in table 1.  Briefly, anthropometric comparisons 
of the 3 groups (Table 1) showed group differences concerning age (F=3.3; df=2; 
P=0.042) and height (F=4.5; df=2; P=0.014) (Table 1). Physical activity was different 
between the groups (F=5.9; df=2; P=0.004) and highest in CTRL.  
Table 1 here 
Regarding medication, more patients with acute depression were treated with 
selective serotonin reuptake inhibitors (acute MDD: 15/34 versus chronic MDD: 1/12; 
χ2=6.1; df=1; P=0.016), and slightly more patients with chronic MDD were treated 
with dopamine and noradrenaline reuptake inhibitor (acute MDD: 4/34 versus chronic 
MDD: 5/12; χ2=3.8; df=1; P=0.094). Regarding treatment with selective serotonin and 
noradrenaline reuptake inhibitors (acute MDD: 6/34; chronic MDD: 2/12), 
agomelatine (acute MDD: 6/34; chronic MDD: 5/12), quetiapine (acute MDD: 2/34; 
chronic MDD: 1/12), and lithium (acute MDD: 1/34; chronic MDD: 0/12), no group 
differences were observed. Of the ten patients with psychotherapy only, 4/16 
were chronic depressed, and 6/34 were acute depressed (χ2=0.7; df=1; P=0.44).  
Employing an ANCOVA with PAT as dependent variable, group and gender as 
independent variable, and age, height and weight as potentially confounding factors 
revealed a significant effect of group (F=7.0; df=2; P=0.002) and gender (F=5.9; df=2; 
P=0.018). Post-hoc analysis revealed significantly increased PAT volume in chronic 
MDD versus acute MDD (p=0.021) and CTRL (P<0.001) respectively, and 
significantly more PAT in acute MDD versus CTRL (P=0.049) (Fig. 1).  
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Insert figure 1 here 
When we stratified our results according to gender, a significant group difference for 
male (F=3.3; df=2; P=0.047) and for female (F=4.0; df=2; P=0.031) was observed. 
The respective post-hoc analyzes revealed significantly higher PAT volume in male 
patients with chronic MDD versus CTRL (P=0.015), and significantly more PAT 
volume in females with chronic MDD versus CTRL (P=0.012). PAT was also 
enlarged among males and females with chronic MDD versus acute MDD, and 
comparing males and females with acute MDD with CTRL, however, these results did 
not reach significance (Fig. 2).  
Insert figure 2 here 
When total volume of adrenal glands, expressed as sum of left and right adrenal 
gland volume, were analyzed, no group differences were observed (F=1.3; df=2; 
P=0.3). However, adrenal gland volume was slightly enlarged in patients with chronic 
MDD > acute MDD > CTRL (Table 1). 
 
 
 
 
Correlates of PAT volumes 
Full details of the correlates of PAT volumes are displayed in table 2.  Briefly, a 
partial correlation analysis controlling for age, weight and height revealed that PAT 
was positively associated with total adrenal gland volume (r= 0.37, P=0.005), and 
with severity of depression (r=0.41; P=0.01 for BDI-2 sum score; r=0.26; P=0.046 for 
MADRS sum score). Fasting cortisol was positively associated with BDI-2 sum score 
(r=0.32; P=0.013) and with MADRS sum score (r=0.36; P=0.006), pointing to 
elevated cortisol dependent on depression severity. TNF-α was associated with 
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MADRS sum score (r=0.31; P=0.016). Physical activity was negatively associated 
with higher depression scores (r= -0.39; P= -0.001, and negatively associated with 
the number metabolic syndrome factors (r=-0.40; P=0.002) (Table 2). 
Insert table 2 here 
Further analyses comprised the potential influence of medication status and 
age at onset of depression on PAT. ANCOVA with PAT as dependent variable, 
treatment status (antidepressant drugs/ no antidepressant drugs) and gender 
as independent variables, and age, height and weight as confounding factors, 
revealed no influence of medication status on the amount of PAT (F=0.01; df=1; 
P=0.90) (data not shown).  
Slightly more patients in the chronic depressed patient group reported an 
onset of the disorder before the age of 20y (8/16 in chronic MDD versus 7/34 in 
acute MDD; χ2=4.4; df=1; P=0.049). ANCOVA with PAT as dependent variable, 
age of onset (before age of 20y/ after age of 20y) and gender as independent 
variables, and age, height and weight as confounding factors, revealed no 
influence of age of depression onset on the amount of PAT (F=0.01; df=1; 
P=0.90) (data not shown).   
 
 
Discussion 
The main finding of our study is that PAT volume is particularly increased in patients 
with chronic depression, compared to patients with acute depression and healthy 
comparison subjects. Thus, our data suggest that the longer the illness duration of 
MDD, the greater a person’s risk of developing increased PAT volume, a key risk 
factor for premature mortality from cardiovascular disease.  Given the importance of 
PAT for the development of coronary artery calcification and myocardial ischemia, 
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our results point to a higher risk for the development of cardiovascular disorders 
(CVD) in patients with MDD, in particular in patients with a chronic disease course.   
 
A recent meta-analytic study has demonstrated that people with MDD are at an 80% 
increased risk of developing coronary heart disease (40).  The precise underlying 
reasons for this increased risk have as yet, not been fully explored.  The association 
of cardiometabolic disorders with severe mental illness has received more attention 
during the last years, leading to a concise monitoring protocol published by the 
European Psychiatric Association in 2009 (41, 42). Since depression is a 
heterogeneous disorder with high frequency in the general population, it is clinically 
important to know whether certain MDD subtypes may carry a higher risk for the 
development of CVD, and should therefore be monitored more closely. Some studies 
pointed to the role of depression severity in the development of CVD (43-45). In the 
study by Windle and colleagues, recurrent depressive disorder was more closely 
related to CVD incidence compared to a single depressive episode (46), and in the 
study by Baune and colleagues, dysthymia was found to be stronger associated with 
CVD compared to unipolar depression (47). Seldenrijk and colleagues reported a 
dose-dependent increase of CVD in MDD over 6y follow-up, with higher CVD risk in 
more severely depressed patients at study entry (48). Taken together the previous 
literature and our results, the role of depression chronicity, recurrence of depression 
and depression severity seem particularly pertinent factors that may be considered in 
estimating CVD risk in MDD. 
 
Another important aspect of our study is the observed higher incidence of the MetS in 
patients with chronic depression compared to acute depression and healthy controls. 
Several studies found an association of MDD with the MetS (49-53). In a recent 
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meta-analysis, an estimated increased risk of having the MetS about 60% was found 
in MDD, compared to healthy controls or data from the general population (17). Our 
results confirm these results and underscore the particular role of a chronic disease 
course for the association between MDD and the MetS.  
 
The third important result of our study is the difference in adrenal gland volumes 
between the groups, showing the highest amount of adrenal gland volume in chronic 
MDD, followed by acute MDD compared to healthy controls. Furthermore, adrenal 
gland volume correlated with the amount of PAT.  An increase in adrenal gland 
volume in MDD has also been reported by others (54, 55). Kessing and coworkers 
reviewed the existing studies on adrenal gland volumes in depression. Three case-
control studies were identified with a total of 89 depressed patients and 57 controls, 
showing enlarged adrenal volume in MDD (54). Adrenal gland volume may serve as 
a proxy marker for hypercortisolism, and has been found to correlate positively with 
dexamethasone-suppressed salivary cortisol and total daily salivary cortisol among 
healthy individuals (56). In a recent study, we found adrenal gland volume enlarged 
in patients with acute depression, and strongly correlated with the amount of intra-
abdominal and pericardial adipose tissue (55).  Our data presented here suggest a 
key role for the hypothalamus-pituitary adrenal axis in the development of heightened 
PAT volume also in severely depressed patients with a chronic disease course.  
 
Relatively few studies have been conducted concerning biological alterations in 
chronic depression. A dysregulation of the hypothalamus-pituitary adrenal axis 
dysregulation in chronic depression has been described in a recent study, depending 
on the subtype of depression (57). Hypercortisolism was particularly observed in 
patients with melancholic subtype of chronic depression. In contrast, in the atypical 
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subtype of chronic depression, metabolic and inflammatory (TNF-α, IL-6) 
dysregulation was observed. Other groups have found increased salivary cortisol in 
recovered depressed patients at high risk for recurrence (58), thereby indicating that 
hypothalamus-pituitary-adrenal dysregulation may be a marker of an unfavorable 
disease course (59). Taken together, these and our findings support the notion that 
chronic forms of MDD are associated with a dysregulation of endocrine (HPAS), 
immune (TNF-α, IL-6) and cardiometabolic (blood pressure regulation, glucose and 
fat metabolism) systems, and that hypercortisolism may possibly underlie medical 
problems associated with chronic forms of depression (60).  
 
However, the link between depression and cardiovascular disease is complex. 
Depression is associated with a number of behavioral cardiovascular risk factors, 
including physical inactivity (61), cigarette smoking, (62) and depressed patients are 
less likely to follow health-promoting behaviors, including maintaining healthy diets 
(63).  Nevertheless, the link between depression and cardiovascular morbidity and 
mortality has been shown to be robust to corrections for behavioral factors, both in 
our study and in the majority of other studies (64).  
 
Other factors potentially contributing to the link between depression and cardiac 
disease include increased concentrations of pro-inflammatory cytokines (specifically 
TNF-α and IL-6), (65) a dysregulation of the hypothalamic-pituitary-adrenal axis, (66) 
endothelial dysfunction, (67, 68) altered platelet activation and aggregation, (69) 
autonomic nervous dysfunction, (70, 71) altered intima-media thickness, (72) 
increased sympathetic and decreased parasympathetic activity, (73) visceral obesity, 
(74-76) and altered glucose disposal (77). Our study adds to these results in 
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demonstrating that PAT is another important factor to be considered, and a chronic 
disease course is more likely to be associated with increased PAT volumes. 
 
Given the potential increased risk of heightened PAT volumes in chronic MDD, our 
data suggest that earlier interventions in the acute phases of illness, seeking to 
ameliorate this risk should be employed and prioritized.  In particular, exercise 
interventions, which have been shown to improve cardiorespiratory levels (78), 
quality of life (79) and depressive symptoms (80).  In the general population, exercise 
is broadly as effective as pharmacological interventions for preventing cardiovascular 
disease and mortality (81).  In addition, interventions seeking to improve diet may 
also be useful to reduce pericardial adipose tissues (82).   
 
Whilst the study adds to the current literature, some limitations should be noted.  We 
did not assess cardiac function or physical capacity in patients and control subjects. 
Moreover, the cross sectional nature of the study precludes any conclusions being 
made regarding the directionality of our results. Therefore, further prospective studies 
are warranted to explore whether PAT is an independent predictor of CVD or 
cardiovascular events. The small number of subjects, in particular in the group of 
chronic depressed patients, limits the generalizability and the explanatory power of 
the study. Further studies with larger samples of acute and chronic depressed 
patients are warranted. We did not differentiate between chronic MDD with 
melancholic versus chronic MDD with atypical disease course. 
 
In summary, we found that PAT and adrenal gland volume were  particularly 
increased in people with chronic MDD versus those with acute MDD or controls.  
Moreover, those with chronic MDD had higher rates of MetS. Given the importance of 
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PAT and the MetS for the development of CVD, chronic MDD may be considered as 
particular at risk group and interventions employed in the earlier stages of the 
disease to ameliorate this risk.   
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Legend Fig. 1: Pericardial adipose tissue (PAT) was enlarged in patients with chronic 
MDD compared to acute MDD and CTRL, and in patients with acute MDD compared 
to CTRL. Bars are presented as mean ± SD, corrected for age, height and weight. A 
P-value <0.05 was considered significant. 
 
Legend Fig. 2: Pericardial adipose tissue (PAT) was increased in female patients with 
chronic MDD > females with acute MDD > CTRL, and in males with chronic MDD > 
males with acute MDD > CTRL. Bars are presented as mean ± SD, corrected for age, 
height and weight. A P-value <0.05 was considered significant. 
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Table 1. Anthropometric, endocrine and cytokine data for patients with acute MDD, 
chronic MDD, and healthy comparison subjects.  
 CTRL 
(N = 25) 
Acute MDD 
(N = 34) 
Chronic MDD 
(N = 16) 
P 
 
Female (N/%) 12 (48%) 16 (47%) 4 (33%) n.s. 
Age (y) 46.8 ± 15.0 41.8 ± 9.6a 37.0 ± 11.7 0.042 
Weight (kg) 79.2 ± 21.0 77.5 ± 19.1 82.8 ± 19.3 n.s. 
Height (m) 1.80 ± 0.13 1.72 ± 0.08 1.77 ± 0.07 0.014 
BMI 24.2 ± 4.8 25.8 ± 4.6 26.2 ± 4.8 n.s. 
BDI (sum) 0.7 ± 1.0 29.5 ± 9.4 31.7 ± 10.6 <0.001 
MADRS (sum) 1.0 ± 1.6 23.2 ± 8.3 25.8 ± 9.4 <0.001 
Physical activity 4.2 ± 1.5 2.7 ± 1.6 2.9 ± 1.9 0.04 
Drinks/wk 3.0 ± 1.5 1.6 ± 3.5 4.6 ± 6.1 0.08 
Smoking (pack-
years) 
2.2 ± 5.3 6.5 ± 9.6 5.0 ± 7.9 n.s. 
BPsyst (mm Hg) 128.4 ± 8.1 129.4 ± 20.8 134.0 ± 13.3 n.s. 
BPdiast (mmHg) 80.0 ± 6.2 81.0 ± 10.1 84.3 ± 10.3 n.s. 
WC (cm) 91.4 ± 15.7 94.3 ± 15.6 94.1 ± 19.6 n.s. 
Triglycerides 
(mmol/L) 
1.17 ± 0.86 1.50 ± 0.73 1.35 ± 0.78 n.s. 
HDL (mmol/L) 1.47 ± 0.37 1.43 ± 0.26 1.41 ± 0.32 n.s. 
Glucose (mmol/L) 5.1 ± 0.5 5.2 ± 0.8 5.4 ± 1.1 n.s. 
Nr. MetS criteria 0.9 ± 1.1 1.3 ± 1.0 1.5 ± 1.6 n.s. 
MetS (N) 2 (8%) 4 (13.3%) 6 (37.5%) 0.028 
Insulin (mU/L) 8.4 ± 4.3 10.4 ± 6.2 11.8 ± 6.4 n.s. 
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HOMA-IR 1.9 ± 1.2 2.4 ± 1.6 2.9 ± 2.0 n.s. 
Cortisol (nmol/L) 423.4±150.1 579.1±162.6 619.9±129.0 <0.001 
IL-6 (pg/mL) 1.7 ± 1.4 1.5 ± 0.8 2.1 ± 2.7 n.s. 
TNF-α (pg/mL) 0.7 ± 0.5 1.7 ± 1.5 1.9 ± 1.3 0.004 
 
Abbreviations: BDI (sum), sum score of the Beck Depression Inventory; BMI, body 
mass index; BPsyst, systolic blood pressure; BPdiast, diastolic blood pressure; HDL, 
high density lipoproteins; HOMA-IR, relative insulin resistance according to 
homeostasis model assessment; IL-6, interleukin 6; MADRS (sum), sum score of the 
Montgomery-Åsperg Depression Rating Scale; MetS, metabolic syndrome; TNF-α, 
tumor necrosis factor-α; WC, waist circumference. Significant results according to 
ANOVA are given in bold. 
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Table 2. Results of the partial correlation analysis. 
 tAGV Cort TNF-α MetS Sport BDI-2 MADRS 
PAT r= 0.37 
P= 0.005 
n.s. n.s. n.s. n.s. r=0.41 
P=0.001 
r=0.26 
P=0.046 
tAGV - n.s. n.s. n.s. n.s. r=0.29 
P=0.024 
n.s. 
Cort - - n.s. n.s. n.s. r=0.32 
P=0.013 
r=0.36 
P=0.006 
TNF-α - - - n.s. n.s. n.s. r=0.31 
P=0.016 
MetS - - - - r=-0.40 
P=-0.002 
n.s. n.s. 
Sport - - - - - r= -0.39 
P= -0.001 
n.s. 
BDI-2 - - - - - - r=1.0 
P<0.001 
 
Partial correlations were performed controlling for age, height and weight. PAT was 
correlated with the total volume of the adrenal glands, and with depression severity. 
Abbreviations: PAT: pericardial adipose tissue; tAGV: total adrenal gland volume; 
Cort: fasting cortisol; TNF- α: tumor-necrosis factor- α; MetS: number of metabolic 
syndrome factors; BDI-2: sum score of the Beck depression Inventory-2; MADRS: 
sum score of the Montgomery-Åsperg Depression Rating Scale. 
